The 36-month beta value for TSHA is at 0.28. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 128.60M, and currently, shorts hold a 12.30% of that float. The average trading volume for TSHA on March 28, 2024 was 2.70M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TSHA) stock’s latest price update
The stock of Taysha Gene Therapies Inc (NASDAQ: TSHA) has increased by 3.59 when compared to last closing price of 3.06. Despite this, the company has experienced a 7.09% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-19 that Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
TSHA’s Market Performance
TSHA’s stock has risen by 7.09% in the past week, with a monthly rise of 29.39% and a quarterly rise of 87.57%. The volatility ratio for the week is 10.13% while the volatility levels for the last 30 days are 12.52% for Taysha Gene Therapies Inc The simple moving average for the last 20 days is 18.11% for TSHA stock, with a simple moving average of 69.08% for the last 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with Jefferies repeating the rating for TSHA by listing it as a “Hold.” The predicted price for TSHA in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 01, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $3, previously predicting the price at $23. The rating they have provided for TSHA stocks is “Equal-Weight” according to the report published on January 27th, 2023.
Goldman gave a rating of “Neutral” to TSHA, setting the target price at $3 in the report published on November 09th of the previous year.
TSHA Trading at 50.49% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.51% of loss for the given period.
Volatility was left at 12.52%, however, over the last 30 days, the volatility rate increased by 10.13%, as shares surge +20.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +107.19% upper at present.
During the last 5 trading sessions, TSHA rose by +7.09%, which changed the moving average for the period of 200-days by +268.60% in comparison to the 20-day moving average, which settled at $2.71. In addition, Taysha Gene Therapies Inc saw 79.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 100,000 shares at the price of $1.63 back on Nov 17 ’23. After this action, Manning Paul B now owns 16,566,667 shares of Taysha Gene Therapies Inc, valued at $163,000 using the latest closing price.
Alam Kamran, the Chief Financial Officer of Taysha Gene Therapies Inc, sale 33,000 shares at $2.33 during a trade that took place back on Aug 24 ’23, which means that Alam Kamran is holding 258,042 shares at $76,890 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -4.66 for the present operating margin
- 0.87 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -7.38. The total capital return value is set at -0.31. Equity return is now at value -294.04, with -56.40 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -35.01.
Currently, EBITDA for the company is -70.0 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 32.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.06.
Conclusion
In conclusion, Taysha Gene Therapies Inc (TSHA) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
